Taribavirin is primarily explored for its antiviral properties, particularly in the treatment of hepatitis C virus (HCV) infections. It functions as a nucleoside analog, inhibiting viral RNA replication by interfering with the viral polymerase enzyme. This mechanism makes it a potential candidate for reducing viral load in patients with chronic hepatitis C. Its application is significant in developing therapeutic strategies, especially for patients who may not respond well to other antiviral treatments. Research continues to assess its efficacy, safety, and potential use in combination therapies for improved outcomes in HCV management.